CMS is proposing to cover positron emission tomography imaging for identification of bone metastasis in patients with a previously diagnosed solid tumor, but only as part of prospective clinical trials, the agency announced Nov. 30. On June 4, CMS opened an internally-generated national coverage analysis on the use of sodium fluoride-18 positron emission tomography (NaF-18 PET) to diagnose bone cancer in patients already treated for another form of cancer.The agency continues to believe there is...